Efavirenz API Manufacturers & Suppliers

Efavirenz (CAS 154598-52-4) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection as part of combination antiretroviral therapy. It is commonly administered with nucleoside reverse transcriptase inhibitors such as lamivudine combined with either zidovudine or tenofovir. Efavirenz is also employed in expanded postexposure prophylaxis regimens to reduce HIV transmission risk following high-risk exposures.

Pharmacologically, efavirenz belongs to the benzoxazine class, compounds characterized by a benzene ring fused to an oxazine ring structure. It acts by non-competitively binding to and inhibiting the reverse transcriptase enzyme, which mediates the conversion of viral RNA to DNA, a critical step in HIV replication. This inhibitory activity prevents the synthesis of proviral DNA and consequently the formation of new virions. Efavirenz requires intracellular phosphorylation to its active triphosphorylated form, although phosphorylation rates vary by cell type. The agent’s antiviral effect is virustatic; it suppresses viral replication but does not eliminate integrated proviral DNA.

In terms of absorption, distribution, metabolism, and excretion (ADME), efavirenz is orally bioavailable, with extensive hepatic metabolism primarily via cytochrome P450 enzymes, notably CYP2B6 and CYP3A4 isoforms. It acts as both a substrate and modulator of multiple CYP enzymes, with inhibitory and inductive effects that may lead to significant drug-drug interactions. Efavirenz is eliminated mainly through hepatic metabolism, with a variable half-life depending on individual metabolic capacity.

Safety considerations include central nervous system-related adverse effects such as dizziness, insomnia, and vivid dreams. Efavirenz carries a moderate risk of QTc prolongation and may affect liver function. Its involvement with multiple cytochrome P450 pathways necessitates careful evaluation during polypharmacy. The drug is contraindicated in pregnancy unless the benefit outweighs the risk, due to potential fetal toxicity in animal studies.

Notable formulations are marketed under brand names such as Sustiva® and Stocrin®, widely used in global antiretroviral treatment programs. Sourcing of efavirenz API requires strict adherence to pharmacopeial standards to ensure purity, stability, and consistent potency. Given its complex metabolic profile, quality control must also consider residual solvent levels and impurity profiles, especially those potentially impacting CYP450 interactions. Reliable supply chains and robust analytical characterization support regulatory compliance and batch-to-batch consistency for clinical and commercial use.